Cognitive Remediation and Supported Education in Psychotic Disorders

Author(s):  
2011 ◽  
Vol 26 ◽  
pp. e85-e86
Author(s):  
Raffaella Torrisi ◽  
Laurent Holzer ◽  
Sandrine Pihet ◽  
Sonja Suter ◽  
A. Aeberhard ◽  
...  

2019 ◽  
Vol 12 (2) ◽  
pp. 164-182 ◽  
Author(s):  
Jaswant Kaur Bajwa ◽  
Bobby Bajwa ◽  
Taras Gula

PurposeThe purpose of this paper is to describe the components, structure and theoretical underpinnings of a cognitive remediation intervention that was delivered within a supported education program for mental health survivors.Design/methodology/approachIn total, 21 participants enrolled in the course Strengthening Memory, Concentration and Learning (PREP 1033 at George Brown College (GBC)) with the diagnosis of depression, anxiety, PTSD, ED and substance use disorder were included in the research. After a baseline assessment, participants completed 14 week cognitive remediation training (CRT) protocol that included six essential components that were integrated and implemented within the course structure of the supported education program at GBC. This was followed by a post-training assessment.FindingsAnalysis of the participants’ performance on CRT protocol using computerized games showed little significant progress. However, the research found a positive change in the self-esteem of the participants that was statistically significant and the findings also aligned with the social and emotional learning framework.Research limitations/implicationsOne of the limitations in the research was the use of computer-assisted cognitive remediation in the form of the HappyNeuron software. The value and relevance of computer assisted needs are to be further examined. It seems that the implementation of the course that explicitly address cognitive challenges creates a supportive environment can be helpful.Practical implicationsDespite the mixed results and the few limitations associated with the CRT intervention reported in the research, the study offers reminders of the complexity of cognitive remediation and all the factors involved that need to be taken into consideration.Social implicationsThis research created explicit space for addressing some of the implicit assumptions about the cognitive abilities when in post-secondary education.Originality/valueThis work is based on author’s previous work on cognitive remediation research within the supported education setting.


2012 ◽  
Vol 63 (5) ◽  
pp. 508-509 ◽  
Author(s):  
Sean A. Kidd ◽  
Jaswant Kaur-Bajwa ◽  
Bahar Haji-Khamneh

CNS Spectrums ◽  
2013 ◽  
Vol 19 (2) ◽  
pp. 115-120 ◽  
Author(s):  
Alice Medalia ◽  
Lewis A. Opler ◽  
Alice M. Saperstein

Cognitive deficits are a prominent and enduring aspect of schizophrenia, which pose a significant barrier to achieving functional goals. The most promising intervention for treating cognitive impairment is cognitive remediation (CR), a behaviorally based therapy associated with medium effect sizes for cognitive and functional outcomes. However, there is a sizeable group of nonresponders whose CR outcomes become limited when the therapeutic approach fails to address individual differences in baseline cognition, motivation variables, and the extent to which CR offers opportunities for generalization. This speaks to a need to develop cognitive interventions that are both personalized and scalable. Emerging data suggest that specific pharmacological agents have the potential to enhance and accelerate behaviorally based CR effects. This article will review the rationale and preliminary evidence to support combining CR and pharmacotherapy. We will review crucial aspects of cognitive interventions that offer the most promise for improving not only cognitive outcomes, but also for enhancing improvement in real-world functioning. Finally, we will address methodological issues to be considered for future research on combined pharmacological and CR interventions.


2014 ◽  
Vol 44 (15) ◽  
pp. 3239-3248 ◽  
Author(s):  
K. E. Lewandowski ◽  
S. H. Sperry ◽  
B. M. Cohen ◽  
D. Öngür

Background.Cognitive dysfunction is a core feature of psychotic disorders; however, substantial variability exists both within and between subjects in terms of cognitive domains of dysfunction, and a clear ‘profile’ of cognitive strengths and weaknesses characteristic of any diagnosis or psychosis as a whole has not emerged. Cluster analysis provides an opportunity to group individuals using a data-driven approach rather than predetermined grouping criteria. While several studies have identified meaningful cognitive clusters in schizophrenia, no study to date has examined cognition in a cross-diagnostic sample of patients with psychotic disorders using a cluster approach. We aimed to examine cognitive variables in a sample of 167 patients with psychosis using cluster methods.Method.Subjects with schizophrenia (n = 41), schizo-affective disorder (n = 53) or bipolar disorder with psychosis (n = 73) were assessed using a battery of cognitive and clinical measures. Cognitive data were analysed using Ward's method, followed by a K-means cluster approach. Clusters were then compared on diagnosis and measures of clinical symptoms, demographic variables and community functioning.Results.A four-cluster solution was selected, including a ‘neuropsychologically normal’ cluster, a globally and significantly impaired cluster, and two clusters of mixed cognitive profiles. Clusters differed on several clinical variables; diagnoses were distributed amongst all clusters, although not evenly.Conclusions.Identification of groups of patients who share similar neurocognitive profiles may help pinpoint relevant neural abnormalities underlying these traits. Such groupings may also hasten the development of individualized treatment approaches, including cognitive remediation tailored to patients' specific cognitive profiles.


2004 ◽  
Vol 39 (4) ◽  
pp. 443-458 ◽  
Author(s):  
Geoff Waghorn ◽  
Megan Still ◽  
David Chant ◽  
Harvey Whiteford

2014 ◽  
Vol 157 (1-3) ◽  
pp. 90-98 ◽  
Author(s):  
Sean A. Kidd ◽  
Jaswant Kaur ◽  
Gursharan Virdee ◽  
Tony P. George ◽  
Kwame McKenzie ◽  
...  

Author(s):  
Tiago Reis Marques ◽  
Shitij Kapur

Current antipsychotic medications have been the mainstay in the treatment of schizophrenia since chlorpromazine was introduced in 1952. However, all antipsychotics share the same mechanism of action, which involves a blockade of the dopamine D2-receptor. This chapter covers recent attempts to develop new treatments for psychotic disorders. These include new approaches to the delivery of existing antipsychotic medications and the most recent and promising mechanisms of action that are distinct from existing antipsychotics. Some of the new mechanisms of action include drugs targeting the glutamatergic system, the alpha7 nicotinic acetylcholine receptor, the phosphodiesterase 10A enzyme, or the muscarinic and serotoninergic system. Finally, we have reviewed a number of alternative nonpharmacological pathways, such as avatar therapy, repetitive transcranial magnetic stimulation, or cognitive remediation. The chapter ends by discussing some of the major challenges facing the development of new treatments for psychotic disorders.


Sign in / Sign up

Export Citation Format

Share Document